Powering the Future: How a Startup Is Targeting Parkinson's Cellular Engines

GAINESVILLE, FL – June 23, 2026 – In the high-stakes world of biotechnology, where promising science often withers in the financial “valley of death” between the lab and the clinic, a major vote of confidence can change everything. For X-tosis, Inc., a fledgling Gainesville-based company, that vote has arrived in the form of a $2.74 million grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF).

The funding is more than just capital; it's a powerful endorsement of a radically different approach to fighting Parkinson's disease, a neurodegenerative disorder that affects over 10 million people globally and has stubbornly resisted all attempts at a cure. Instead of managing symptoms, X-tosis aims to repair the disease at one of its most fundamental origins: the cellular powerhouses known as mitochondria. The grant will accelerate the development of its lead drug candidate, XTS001, toward the critical milestone of human clinical trials, offering a new form of hope for a patient community in desperate need of a breakthrough.

Recharging the Fight: A New Focus on the Cell's Powerhouse

For years, the standard of care for Parkinson's has focused on replenishing dopamine, a neurotransmitter lost as specific neurons in the brain die off. While these treatments can manage motor symptoms like tremors and stiffness, they do nothing to stop the relentless progression of the underlying disease. X-tosis is part of a new wave of companies looking further upstream to find the root cause of that neuronal death.

Their focus is mitochondrial dysfunction, a pathological process now widely recognized as a central driver of Parkinson's. Mitochondria are the microscopic engines in every cell, responsible for generating the energy that powers life. In Parkinson's patients, these engines begin to fail. A key culprit in this failure is a protein called the voltage-dependent anion channel 1, or VDAC1. Acting as a crucial gatekeeper on the mitochondrial surface, VDAC1 controls the flow of molecules essential for energy production and cell survival. Under stress, however, VDAC1 proteins can clump together, or “oligomerize,” forming large, unregulated pores. This catastrophic event short-circuits the mitochondrion, leading to energy failure, inflammation, and the release of signals that trigger programmed cell death, or apoptosis.

X-tosis's lead candidate, XTS001, is a small-molecule drug designed to stop this from happening. It acts as a stabilizer, selectively inhibiting VDAC1 oligomerization and keeping the mitochondrial gates functioning correctly. The scientific foundation for this approach is the result of over five decades of pioneering research by Professor Varda Shoshan-Barmatz, a global leader in mitochondrial biology whose work, with over 225 publications, forms the bedrock of the company's patented MitoXTS platform.

“By preserving mitochondrial integrity upstream in the neurodegeneration cascade, we aim to shift treatment from symptomatic relief to targeting underlying disease biology,” said Yotam Nisemblat, Chief Scientific Officer of X-tosis. The promise is profound: a therapy that doesn't just mask the disease but actively protects neurons from dying in the first place.

The Foundation as a Catalyst: De-Risking Deep-Tech Biology

The grant from MJFF is a textbook example of how strategic, non-profit funding can catalyze innovation in areas that traditional venture capital might deem too risky. MJFF’s Parkinson's Disease Therapeutics Pipeline Program is specifically designed to identify and de-risk the most promising early-stage science, providing the non-dilutive funding necessary to bridge the gap to larger-scale investment.

“This award from The Michael J. Fox Foundation is more than funding; it is support for further investigation of our scientific approach that mitochondrial dysfunction is a central addressable driver of Parkinson’s disease,” stated Erin Henderson, CEO of X-tosis, Inc.

For a startup like X-tosis, founded just two years ago in 2024, this type of support is invaluable. It allows the company to pursue its ambitious scientific goals without surrendering significant equity early on. More importantly, it serves as a rigorous, peer-reviewed validation that resonates powerfully with the broader investment community. “MJFF isn't just writing a check; they're placing a strategic bet,” noted one biotech industry analyst. “This kind of validation acts as a powerful signal to venture capital and pharmaceutical partners, essentially saying, 'The science here is sound, and the patient need is urgent.' It can shave years off the fundraising and partnership timeline.”

This model is becoming increasingly crucial for tackling complex diseases like Parkinson's, where the path to a marketable drug is long, expensive, and fraught with uncertainty. By absorbing some of the initial risk, foundations like MJFF ensure that truly novel ideas have a chance to prove their worth.

From Lab Bench to Clinical Hope: Navigating the Path to Patients

The $2.74 million will be put to immediate and critical use. The funds are earmarked for the final preclinical steps required before X-tosis can file an Investigational New Drug (IND) application with the FDA—the official green light to begin human testing. This includes confirmatory safety and efficacy studies in animal models, manufacturing process development, and crucial biomarker work to identify measurable indicators of the drug’s effect in the body.

Preclinical studies have already shown remarkable promise. In animal models of Parkinson's, compounds from the MitoXTS platform have been shown to reduce the loss of dopamine-producing neurons, restore dopamine levels, and protect against key pathologies associated with the disease. The goal now is to replicate and expand upon these findings in the rigorous, standardized format required by regulators.

“With MJFF’s support, we are accelerating toward IND-enabling studies and positioning XTS001 as a potential therapeutic approach for Parkinson’s disease and beyond,” Henderson affirmed. Guiding this effort is a leadership team that blends deep scientific expertise with seasoned business acumen, a combination essential for navigating the complex journey ahead.

Neurologists on the front lines are watching such developments with cautious optimism. “For decades, our toolkit has been limited to helping patients cope with symptoms as their condition inevitably worsens,” commented a neurologist specializing in movement disorders who is not involved with the company. “An upstream, disease-modifying therapy that targets a core mechanism like mitochondrial health would be the Holy Grail. The preclinical data is compelling, but the journey through multi-phase clinical trials is where the true test lies for any new candidate.”

A Platform of Precision: Beyond a Single Disease

While Parkinson's is the immediate target, the implications of X-tosis's technology extend far wider. The MitoXTS platform is not a single-drug technology but a versatile engine for developing precision mitochondrial therapeutics. Since VDAC1-driven mitochondrial dysfunction is implicated in a host of other devastating neurodegenerative conditions, the company is also advancing its pipeline to address Alzheimer's disease, ALS, and related disorders.

This platform approach makes X-tosis a more formidable player in the biotech landscape, diversifying its risk and dramatically expanding its potential market and human impact. Preclinical work in Alzheimer's models has already demonstrated the platform's ability to reduce amyloid-beta burden and improve cognitive performance, suggesting the core mechanism is relevant across different disease pathologies. If the fundamental principle of restoring mitochondrial health proves effective in Parkinson's, it could unlock a new frontier in the treatment of brain diseases, transforming a startup's focused quest into a broad-based revolution in neurological medicine.